



Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

**Press Release**  
March 27, 2015

BSE: 532531  
NSE: STAR

---

## **Strides Arcolab announces the launch of generic drug Sofosbuvir in India under the brand name 'Virso'**

---

**Bangalore, March 27, 2015: Strides Arcolab Limited (Strides)** today announced the launch of generic drug Sofosbuvir in India under the brand name '**Virso**'. In September 2014, Strides entered into a licensing agreement with Gilead Sciences, Inc to bring Hepatitis C cure to 91 developing countries. The product will be available to Indian patients shortly.

Sofosbuvir is the first-in-class NS5B polymerase inhibitor to be launched in India for Hepatitis C treatment and represents a paradigm shift in the existing Hepatitis C management. The high potency, high barrier to resistance, pan genotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions of Sofosbuvir makes it a breakthrough drug in Hepatitis C treatment. This drug in combination therapy has shown to have high cure rates of around 90%.

Globally, it is estimated that 170-185 million people (about 3% of the world's population) are chronically infected with Hepatitis C virus (HCV). In India alone, it is estimated that 12-18 million patients are infected with Hepatitis C, which is several fold greater than those with HIV/AIDS.

Commenting on the announcement, Mohan Kumar, CEO-Pharma stated "We are pleased to announce this launch in partnership with Gilead Sciences, which is a big leap in our commitment towards bringing critical healthcare at affordable cost."

The launch in other markets is subject to approvals from the regulatory authorities in respective countries.

### **About Strides Arcolab Limited**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products. The Company has 8 manufacturing facilities presence in more than 75 countries in developed and emerging markets. Additional information is available at the Company's website at [www.stridesarco.com](http://www.stridesarco.com).

For further information, please contact:

|   |   |
|---|---|
| <p><b><u>Strides</u></b></p> <p>Mohan Kumar,<br/>CEO –Pharma<br/>+91 80 6784 0748</p> <p>Vikesh Kumar +91 80 6784 0827<br/>Kannan. N: +91 98450 54745</p> | <p><b><u>PR Consultancy</u></b></p> <p><b>Fortuna PR</b><br/>K Srinivas Reddy: +91 9000527213<br/>srinivas@fortunapr.in</p> <p>K Priya: +91 9535425418<br/>priya@fortunapr.in</p> |
|---|---|